title: Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study.
abstract: OBJECTIVE
  The FINESSE-ANGIO (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events-Angiographic) study evaluated acute treatment effects on infarct-related artery (IRA) patency and angiographic correlates of coronary microcirculatory function.
  
  
  BACKGROUND
  The FINESSE trial evaluated the effects on clinical outcomes of primary percutaneous coronary intervention (PCI) facilitated with pre-catheterization laboratory administration of abciximab with half-dose reteplase (combination-facilitated group), abciximab alone (abciximab-facilitated group), or with abciximab administered immediately before the procedure (primary PCI).
  
  
  METHODS
  The FINESSE-ANGIO substudy compared the effects of the 3 treatment strategies on patency (TIMI [Thrombolysis In Myocardial Infarction] flow grade 2/3) of the IRA at basal coronary angiography. The secondary efficacy end points were corrected TIMI frame count, percentage of patients achieving TIMI flow grade 3, and the percentage achieving myocardial blush grade 2/3 of the IRA at post-PCI angiography. All angiographies were evaluated at a central core laboratory.
  
  
  RESULTS
  Of the 2,452 FINESSE patients, 637 were included in the FINESSE-ANGIO substudy. Patients in the combination-facilitated group exhibited significantly higher rates of baseline IRA patency compared with the abciximab-facilitated and the primary PCI groups (76.1% vs. 43.7% and 32.7%, respectively; p < 0.0001 for both; p = 0.025 abciximab-facilitated vs. primary PCI). There were no significant differences in the post-PCI corrected TIMI frame count (17.1 ± 15.8, 17.4 ± 17.3, and 15.8 ± 14.1) or the rates of post-PCI TIMI flow grade 3 (79.8%, 77.7%, and 76.6%), myocardial blush grade 2/3 (85.6%, 79.5%, and 86.4%), respectively.
  
  
  CONCLUSIONS
  Pre-catheterization laboratory administration of abciximab alone and especially in combination with half-dose reteplase resulted in higher rates of IRA patency at baseline coronary angiography compared with no pre-treatment. However, post-procedural angiographic and microcirculatory variables were unaffected by facilitation therapy.
authors.affiliation: San Giovanni Hospital and Centro per la Lotta Contro l'Infarto, Fondazione Onlus, Via dell’amba Aradam 9, Rome, Italy. fprati@hsangiovanni.roma.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Prati
authors.forename: Sonia
authors.initials: S
authors.lastname: Petronio
authors.forename: Ad J
authors.initials: AJ
authors.lastname: Van Boven
authors.forename: Michal
authors.initials: M
authors.lastname: Tendera
authors.forename: Leonardo
authors.initials: L
authors.lastname: De Luca
authors.forename: Mark A
authors.initials: MA
authors.lastname: de Belder
authors.forename: Alfredo R
authors.initials: AR
authors.lastname: Galassi
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Imola
authors.forename: Gilles
authors.initials: G
authors.lastname: Montalescot
authors.forename: Jan Z
authors.initials: JZ
authors.lastname: Peruga
authors.forename: Elliot S
authors.initials: ES
authors.lastname: Barnathan
authors.forename: Stephen
authors.initials: S
authors.lastname: Ellis
authors.forename: Stefano
authors.initials: S
authors.lastname: Savonitto
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000628:therapy; D003331:Coronary Vessels / Q000473:pathology*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D053805:Fractional Flow Reserve, Myocardial; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D015425:Myocardial Reperfusion; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018709:Statistics, Nonparametric; D014654:Vascular Patency
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077284:Abciximab